Patient-reported outcomes as endpoints in clinical trials of kidney transplantation interventions
Patient-reported outcomes (PROs) that assess individuals’ perceptions of life participation, medication adherence, disease symptoms, and therapy side effects are extremely relevant in the context of kidney transplantation. All PROs are potentially suitable as primary or secondary endpoints in interv...
Main Authors: | Tong, A, Oberbauer, R, Bellini, MI, Budde, K, Caskey, FJ, Dobbels, F, Pengel, L, Rostaing, L, Schneeberger, S, Naesens, M |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Frontiers Media
2022
|
Similar Items
-
Allograft function as endpoint for clinical trials in kidney transplantation
by: Hilbrands, L, et al.
Published: (2022) -
Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation
by: Naesens, M, et al.
Published: (2022) -
Proposed definitions of antibody-mediated rejection for use as a clinical trial endpoint in kidney transplantation
by: Roufosse, C, et al.
Published: (2022) -
Proposed definitions of T cell-mediated rejection and tubulointerstitial inflammation as clinical trial endpoints in kidney transplantation
by: Seron, D, et al.
Published: (2022) -
Alloimmune risk stratification for kidney transplant rejection
by: Bestard, O, et al.
Published: (2022)